US 12,227,564 B2
Anti-GDF15 antibodies, compositions and methods of use
Kevin Charles Beaumont, Littleton, MA (US); Danna M. Breen, Stow, MA (US); Matthew Allister Lambert, Dublin (IE); Jeffrey Raymond Chabot, Medford, MA (US); Tao He, Acton, MA (US); Ksenya Shchors, San Mateo, CA (US); and James R. Apgar, Medford, MA (US)
Assigned to PFIZER INC., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Aug. 1, 2022, as Appl. No. 17/816,484.
Application 17/816,484 is a division of application No. 16/541,817, filed on Aug. 15, 2019, granted, now 11,566,066.
Claims priority of provisional application 62/881,064, filed on Jul. 31, 2019.
Claims priority of provisional application 62/750,393, filed on Oct. 25, 2018.
Claims priority of provisional application 62/750,479, filed on Oct. 25, 2018.
Claims priority of provisional application 62/765,289, filed on Aug. 20, 2018.
Prior Publication US 2022/0380448 A1, Dec. 1, 2022
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/22 (2013.01) [A61P 35/00 (2018.01); A61K 39/395 (2013.01); A61K 39/39533 (2013.01); A61K 39/3955 (2013.01); C07K 16/244 (2013.01); C07K 16/2818 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01)] 5 Claims
 
1. A method of treating a medical condition, disease or disorder mediated by or associated with expression of GDF15, in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of an antibody, or antigen binding fragment thereof, that specifically binds to human growth differentiation factor 15 (GDF15), comprising
a light chain complementarity determining region 1 (LCDR-1) comprising the amino acid sequence of SEQ ID NO:95, a LCDR-2 comprising the amino acid sequence of SEQ ID NO:28, and a LCDR-3 comprising the amino acid sequence of SEQ ID NO:9, and a heavy chain complementarity determining region 1 (HCDR-1) comprising the amino acid sequence of SEQ ID NO:32, a HCDR-2 comprising the amino acid sequence of SEQ ID NO:165, and a HCDR-3 comprising the amino acid sequence of SEQ ID NO:52,
and wherein the medical condition, disease or disorder mediated by or associated with expression of GDF15 is cachexia not associated with another medical condition or cachexia associated with cancer, chemotherapy, chemotherapy in combination with an immuno-oncology therapy, chronic obstructive pulmonary disease, chronic kidney disease, chronic heart failure, congestive heart failure, or sarcopenia.